[1]刘申颖,施彦卿,梅鹏飞,等.超声引导下经皮无水乙醇注射联合射频消融治疗中晚期肝癌的效果[J].医学信息,2019,32(22):87-90.[doi:10.3969/j.issn.1006-1959.2019.22.026]
　LIU Shen-ying,SHI Yan-qing,MEI Peng-fei,et al.Ultrasound-guided Percutaneous Ethanol Injection Combined with Radiofrequency Ablation for Advanced Hepatocellular Carcinoma[J].Journal of Medical Information,2019,32(22):87-90.[doi:10.3969/j.issn.1006-1959.2019.22.026]
点击复制

超声引导下经皮无水乙醇注射联合射频消融治疗中晚期肝癌的效果()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年22期
页码:
87-90
栏目:
论著
出版日期:
2019-11-15

文章信息/Info

Title:
Ultrasound-guided Percutaneous Ethanol Injection Combined with Radiofrequency Ablation for Advanced Hepatocellular Carcinoma
文章编号:
1006-1959（2019）22-0087-04
作者:
刘申颖1; 2; 施彦卿1; 2; 梅鹏飞1; 2; 李志英1; 2; 雷 霞 1; 2
（1.九江学院附属医院消化内科，江西 九江 332000；2.九江学院附属消化内科研究所，江西 九江 332000）
Author(s):
LIU Shen-ying1; 2; SHI Yan-qing1; 2; MEI Peng-fei1; 2; LI Zhi-ying1; 2; LEI Xia1; 2
(1.Department of Gastroenterology,Affiliated Hospital of Jiujiang University,Jiujiang 332000,Jiangxi,China;2.Institute of Gastroenterology,Jiujiang University,Jiujiang 332000,Jiangxi,China)
关键词:
经皮无水乙醇注射; 经皮射频消融术; 肝癌; 存活率; 谷丙转氨酶; 总胆红素
Keywords:
Percutaneous ethanol injection; Percutaneous radiofrequency ablation; Liver cancer; Survival rate; Alanine aminotransferase; Total bilirubin
分类号:
R735.7
DOI:
10.3969/j.issn.1006-1959.2019.22.026
文献标志码:
A
摘要:
目的 观察超声引导下经皮无水乙醇注射（PEI）联合经皮射频消融（PRFA）治疗中晚期肝癌（HCC）的临床有效性和安全性。方法 选择2010年1月~2016年12在我院诊断为Ⅲ~Ⅳ期HCC的患者85例，根据数字随机法分为A（28例）、B（29例）、C（28例）三组，A组患者用PEI开始治疗，1~2周后予PRFA治疗；B组患者先行PRFA治疗，1~2周后行PEI治疗；C组患者同时接受PEI和PRFA治疗。随访6个月~3年，比较三组患者生存率、肿瘤消融坏死体积、消融后体积、完全消融率、无水乙醇用量、射频能量及肝功能损害指数（谷丙转氨酶和总胆红素水平）。结果 A组患者生存率高于B组和C组，差异有统计学意义（P＜0.05）；B组肿瘤消融坏死体积大于A组和C组，差异有统计学意义（P＜0.05）；B组消融后体积小于A组和C组，差异有统计学意义（P＜0.05）；B组完全消融率为82.76%，高于A组的71.43%和C组的64.29%，差异有统计学意义（P＜0.05）；三组患者无水乙醇用量、射频能量能比较，差异无统计学意义（P＞0.05）；三组治疗前后谷丙转氨酶和总胆红素水平比较，差异无统计学意义（P＞0.05）。结论 PEI和PRFA治疗中晚期肝癌安全且有效的，其中以PEI联合PRFA序贯治疗效果为佳。
Abstract:
Objective To observe the clinical efficacy and safety of ultrasound-guided percutaneous ethanol injection (PEI) combined with percutaneous radiofrequency ablation (PRFA) in the treatment of advanced liver cancer (HCC). Methods 85 patients with stage III~IV HCC diagnosed in our hospital from January 2010 to December 2016 were enrolled. According to the numerical randomization method, they were divided into three groups: A (28 cases), B (29 cases) and C (28 cases). Patients in group A were treated with PEI and treated with PRFA 1 to 2 weeks later. Group B patients were treated with PRFA first, and PEI was treated 1 to 2 weeks later. Group C patients were treated with PEI and PRFA. After 6 months to 3 years of follow-up, the survival rate, tumor ablation necrosis volume, ablation volume, complete ablation rate, absolute ethanol dosage, radiofrequency energy and liver function damage index (alanine aminotransferase and total bilirubin levels) were compared between the three groups. Results The survival rate of patients in group A was higher than that in group B and C,the difference was statistically significant (P<0.05). The tumor ablation necrosis volume in group B was greater than that in group A and group C, the difference was statistically significant (P<0.05). The volume of group B after ablation was smaller than group A and group C,the difference was statistically significant(P<0.05); the complete ablation rate of group B was 82.76%, higher than 71.43% in group A and 64.29% in group C, the difference was statistically significant (P<0.05); the amount of absolute ethanol in the three groups,there was no significant difference in radiofrequency energy (P>0.05). There was no significant difference in the levels of alanine aminotransferase and total bilirubin between the three groups before and after treatment (P>0.05). Conclusion PEI and PRFA are safe and effective in the treatment of advanced liver cancer. The sequential treatment with PEI combined with PRFA is better.

参考文献/References:

[1]Ozakyol A.Global Epidemiology of Hepatocellular Carcinoma (HCC Epidemiology)[J].Journal of Gastrointestinal Cancer,2017,48(3):238-240. [2]Ghouri YA,Mian I,Rowe JH.Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis[J].Journal of Carcinogenesis,2017,16(1):1. [3]Hou W,Zhu X.Extra vascular interventional treatment of liver cancer, present and future[J].Drug Discoveries & Therapeutics,2015,9(5):335-341. [4]Song P,Wang M,Ning WU,et al.Interventional therapy for primary hepatic carcinoma associated with IVC- RA tumor thrombus:initial experience in 17 cases[J].Journal of Interventional Radiology,2017,26(2):129-132.. [5]Xu L T,Zhou ZH,Lin JH,et al.Clinical study of transarterial chemoembolization combined with 3-dimensional conformal radiotherapy for hepatocellular carcinoma[J].European Journal of Surgical Oncology,2011,37(3):250-251. [6]Nouso K,Kariyama K,Nakamura S,et al.Application of Radiofrequency Ablation for the Treatment of Intermediate-Stage Hepatocellular Carcinoma[J].Journal of Gastroenterology & Hepatology,2017,32(3):695. [7]Chen S,Peng Z,Lin M,et al.Combined percutaneous radiofrequency ablation and ethanol injection versus hepatic resection for 2.1~5.0 cm solitary hepatocellular carcinoma: a retrospective comparative multicentre study[J].European Radiology,2018,28(9):3651-3660. [8]Peng C,Zhang Z,Liu J,et al.Efficacy and safety of ultrasound-guided radiofrequency ablation of hyperplastic parathyroid gland for secondary hyperparathyroidism associated with chronic kidney disease[J].Head & Neck,2017,39(3):564. [9]Wu J,Chen P,Xie YG,et al.Comparison of the effectiveness and safety of ultrasound- and CT-guided percutaneous radiofrequency ablation of non-operation hepatocellular carcinoma[J].Pathology & Oncology Research,2015,21(3):637-642. [10]Zhang W,Luo E,Gan J,et al.Long-term survival of hepatocellular carcinoma after percutaneous radiofrequency ablation guided by ultrasound[J].World Journal of Surgical Oncology,2017,15(1):122. [11]Clark TW.Chemical ablation of liver cancer[J].Techniques in Vascular & Interventional Radiology,2007,10(1):58-63. [12]Shiina S.Percutaneous ethanol injection therapy for hepatocellular-carcinoma (review)[J].International Journal of Oncology,1993,2(4):669. [13]Livraghi T,Giorgio A,Marin G,et al.Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection[J].Radiology,1995,197(1):101-108. [14]Rossi S.Percutaneous Radiofrequency Interstitial Thermal Ablation in the treatment of small hepatocellular carcinoma[J].Cancer J Sci Am,1995,1(1):73-81. [15]Wahl DR,Stenmark MH,Tao Y,et al.Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma[J].Journal of Clinical Oncology,2015,34(5):452. [16]Kai L,Jia L,Zhi-Gang W,et al.Ultrasonic guided percutaneous ethanol injection with or without combined radiofrequency ablation for hepatocellular carcinomas[J].Indian Journal of Cancer,2015,52 Suppl(6):E102. [17]Rehman J,Landman J,Lee D,et al.Needle-Based Ablation of Renal Parenchyma Using Microwave, Cryoablation, Impedance- and Temperature-Based Monopolar and Bipolar Radiofrequency, and Liquid and Gel Chemoablation: Laboratory Studies and Review of the Literature[J].Journal of Endourology,2004,18(1):83-104. [18]Ogasawara S,Chiba T,Ooka Y,et al.Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib[J].Investigational New Drugs,2016,34(2):255-260.

更新日期/Last Update: 2019-11-15